Local Effect of Intramuscular Injection of Meloxicam and Diclofenac: an Experimental, Comparative and Histological Study

Total Page:16

File Type:pdf, Size:1020Kb

Local Effect of Intramuscular Injection of Meloxicam and Diclofenac: an Experimental, Comparative and Histological Study Local Effect of Intramuscular Injection of Meloxicam.. Ahmed Hisham Qassim Local Effect of Intramuscular Injection of Meloxicam and Diclofenac: An Experimental, Comparative and Histological Study Ahmed Hisham Qassim* , Omar Riadh Hamdi* , Ashraf Abdulraheem Ayoob* , Mohammed Taib Taher* *Department of Anatomy, Histology and Embryology, College of Medicine, University of Mosul, Mosul, Iraq. Correspondence:[email protected] (Ann Coll Med Mosul 2019; 41 (2):163-169). Received:17th Oct. 2019; Accepted: 15th Dec. 2019. ABSTRACT Objectives: To compare the local effect of therapeutic doses of meloxicam and diclofenac on the muscle of rats at different periods by intramuscular injection. Materials and methods: Thirty six adult albino rats were divided equally into 6 groups. The 1st and 2nd groups were injected intramuscularly with normal saline for 2 and 4 weeks respectively, the 3rd and 4th groups were injected intramuscularly with meloxicam for 2 and 4 weeks respectively, the last 2 groups were injected intramuscularly with diclofenac sodium also for 2 and 4 weeks respectively. The drugs were injected into the quadriceps femoris muscle of the right femur once each day till the end of the period stated. The specimens were histologically processed, stained with hematoxylin and eosin and examined with light microscope. Results: No changes were seen in quadriceps femoris muscles of groups 1, 2, 3 and 4, whereas group 5 showed congested blood vessels within normal muscle tissue. In Group 6 mononuclear inflammatory cells infiltration, vascular congestion, fibrosis, degenerative changes and muscle tissue necrosis were seen. Conclusion: Meloxicam is safer than diclofenac sodium on muscular tissue after a long-term daily intramuscular injection. Keyword: meloxicam, diclofenac, intramuscular injection, muscle tissue. التأثير الموضعي للحقن العضلي لعقاري الميلوكسيكام والدكلوفيناك: دراسة تجريبية, مقارنة و نسيجية . احوذ هشام قاسن* ، عور رياض حوذي* ، اشرف عبذ الرحين ايىب* ، هحوذ طية طاهر جرجيس* *فرع التشريح واﻻنسجة واﻻجنة، كلية الطة ، جاهعة الوىصل، الوىصل ، العراق الخﻻصة الهذف هن الذراسة: دساست هقاسًت الخأثٍش الوىضعً للدشع العﻻخٍت لعقاسي الوٍلىكسٍكام والذكلىفٌٍاك صىدٌىم على عضلت الدشراى بعذ فخشاث هخخلفت هي الحقي العضلً. اﻷدوات والطرق: سخت وثﻻثىى هي ركىس الدشراى البٍضاء قسوىا الى سج هداهٍع هخساوٌت. الوداهٍع حقٌج عضلٍاً باﻷدوٌت الخالٍت وبالخشحٍب, هحلىل هلحً عٍاسي لوذة أسبىعٍي وأسبعت أسابٍع؛ عقاس الوٍلىكسٍكام )2,00 هلغ/كغن( لوذة أسبىعٍي وأسبعت أسابٍع؛ عقاس الذكلىفٌٍاك صىدٌىم )0,0 هلغ/كغن( لوذة أسبىعٍي وأسبعت أسابٍع. اﻷدوٌت حن حقٌها فً العضلت سباعٍت الشأس للفخز اﻷٌوي هشة فً الٍىم إلى ًهاٌت الفخشة الوحذدة. حن ححضٍش الٌوارج ًسٍدٍاً وصبغج بالهٍواحىكسلٍي واﻻٌىسٍي وفحصج بالودهش الضىئً. النتائج: لن ٌﻻحظ أي حغٍش ًسٍدً فً العضﻻث للوداهٍع 1, 0, 3 و 4 ولكي الودوىعت 5 أظهشث احخقاى لﻷوعٍت الذهىٌت فً ًسٍح العضلت. أها الودوىعت 6 فأظهشث اًسﻻل خﻻٌا الخهابٍت احادٌت الٌىاة, احخقاى وعائً دهىي , حلٍف, إضافت إلى حغٍشاث ححللٍت وًخش فً الٌسٍح العضلً. اﻻستنتاج: عقاس الوٍلىكسٍكام أكثش أهاًاً هي عقاس الذكلىفٌٍاك صىدٌىم على الٌسٍح العضلً بعذ فخشة طىٌلت هي الحقي العضلً الٍىهً. Ann Coll Med Mosul December 2019 Vol. 41 No. 2 163 Ahmed Hisham Qassim Local Effect of Intramuscular Injection of Meloxicam.. الكلوات الوفتاحية: هٍلىكسٍكام, الذكلىفٌٍاك صىدٌىم, الحقي العضلً, الٌسٍح العضلً. INTRODUCTION ystemic and topical nonsteroidal anti- special plastic cages under ideal conditions. The S inflammatory drugs(NSAIDs) are the most number of animals in each cage was three. Food commonly prescribed drugs in the treatment of and water were available ad libitum throughout the inflammation and pain associated with chronic study. inflammatory conditions like rheumatoid arthritis and osteoarthritis1-5. They reduce inflammation by Drugs ® reducing prostaglandin synthesis through inhibition Meloxicam (Mobic , Boehringer Ingelheim, ® of cyclooxygenase enzyme(COX)6. COX-1 and Germany) and diclofenac sodium (Refen , COX-2 are isoforms of the enzyme, suppression of Hemofarm, Serbia) in the form of ampoules were COX-2 is responsible for the therapeutic gain of purchased from a common commercial supply NSAIDs, while their adverse effects result from (Alradwan drug store). The drugs were inhibition of COX-17. administered in therapeutic doses similar to that 23 The route of administration of NSAIDs is given to human . Which were calculated by (24) considered to be an important field for diluting the drugs with normal saline. The drugs investigation, because these drugs can be given were injected intramuscularly into the quadriceps orally, intramuscularly, rectally and intra-articularly femoris muscle of the right femur of the rat every in addition, they can be applied locally on mucosa day till the end of the stated period according to and skin8-10. Thus a lot of researches had been the subdivided groups. carried out with results showing that intramuscular Groups And Experimental Design administration had some advantages over oral After one week of acclimatization, the animals route in that it has faster onset of action, avoids were divided into six groups, each consisted of six first pass metabolism, besides, it prevents direct rats. contact of the drug with gastric mucosa8,11-14. On the contrary, intramuscular route can cause tissue Control Groups necrosis at the site of injection even after a short Groups 1 and 2: received a single daily 15,16 term use . intramuscular injection of normal saline (1ml/ Kg) Since meloxicam is a preferentially selective for 2 and 4 weeks respectively. COX-2 inhibitor, whereas diclofenac sodium is a 17,18 nonselective COX inhibitor . several Treated Groups researchers had studied the efficacy, tolerability, -Group 3: animals received a single daily as well as the safety of meloxicam and compared it intramuscular injection of 0.22mg/ kg of meloxicam with diclofenac after a short period of intramuscular for 2 weeks. injection or after a long period of oral -Group 4: is similar to that of group 3, but the drug administration in both experimental animals and is given for 4 weeks. humans19-22. -Group 5: rats were daily intramuscularly injected The aim of the present study is to compare the with a single dose of diclofenac sodium (2.2 mg/ local effect of therapeutic doses of meloxicam and kg) for 2 weeks. diclofenac on rats’ muscle given for the same -Group 6: is similar to that of group 5, but the drug periods as an intramuscular injection. is given for 4 weeks. Twenty four hours after the last injection, rats MATERIALS AND METHODS were killed by inhaling overdose of Ether. Animals Dissection of the right hind limbs was done and the Thirty six male adult albino rats were obtained quadriceps femoris muscle was removed from from the animal house of Experimental Research each animal and prepared for histological Unit, College of Medicine, University of Mosul, processing. Iraq. The animals were kept in the laboratory in 164 Ann Coll Med Mosul December 2019 Vol. 41 No. 2 Local Effect of Intramuscular Injection of Meloxicam.. Ahmed Hisham Qassim Histological Study The quadriceps femoris muscle tissue samples were fixed in 10% neutral buffered formalin for 24 hours, then they were dehydrated, cleared, embedded in paraffin and sectioned by the microtome into sections of 5µm thickness, thereafter the sections were mounted on glass slides and stained with hematoxylin and eosin. The histological slides were examined through Olympus light microscope, and several sections were chosen to obtain their photographs using a digital camera. Figure 2: Photomicrograph of quadriceps femoris muscle of group 4 showing normal morphology. RESULTS (H&E X 100). Control (Untreated) Groups: In groups 1 and 2, the histological changes in the muscular biopsy were unremarkable (Figure 1). Treated Groups In groups 3 and 4, microscopic examination was similar to that of control groups (Figure 2). In animals of group 5, the histological finding was only congested skeletal muscle fibers(Figure 3). However, in group 6, the histological sections revealed mononuclear inflammatory cells infiltration, vascular congestion, fibrosis, degenerative changes and muscle tissue necrosis. Moreover, several areas showed hemorrhage which could be of traumatic origin (Figures 4 and Figure 3: Photomicrograph of quadriceps femoris muscle of group 5 showing congested blood vessels 5, Table 1). within normal muscle tissue (arrows). (H&E X 100). Figure 1: Photomicrograph of quadriceps femoris muscle of control groups showing normal Figure 4: Photomicrograph of quadriceps femoris morphology. (H&E X 100). muscle of group 6 showing mononuclear inflammatory cells infiltration (black arrow), vascular congestion (v), fibrosis (white arrow) and degenerative changes of muscle tissue (arrowhead). (H&E X 100). Ann Coll Med Mosul December 2019 Vol. 41 No. 2 165 Ahmed Hisham Qassim Local Effect of Intramuscular Injection of Meloxicam.. Figure 5: Photomicrograph of quadriceps femoris muscle of group 6 showing muscle tissue necrosis (black arrow) and hemorrhage (white arrow). (H&E X 100). Table 1: Showing drugs administered with their doses and duration of administration, as well as, histological changes of quadriceps femoris muscle obtained in different groups. Duration of Drug Dose of the Groups administrati Histological changes of muscle administered drug on Group 1 Normal saline 1 ml / kg 2 weeks Normal muscle tissue Group 2 Normal saline 1 ml / kg 4 weeks Normal muscle tissue Group 3 Meloxicam 0.22 mg / kg 2 weeks Normal muscle tissue Group 4 Meloxicam 0.22 mg / kg 4 weeks Normal muscle tissue Congestion of blood vessels within normal
Recommended publications
  • Meloxicam 15 Mg Orodispersible Tablets Meloxicam 15.0 Mg
    PACKAGE LEAFLET: INFORMATION FOR THE USER Meloxicam 15 mg Orodispersible Tablets Meloxicam 15.0 mg Read all of this leaflet carefully before you start taking may occur if you have serious blood loss or burns, surgery or low this medicine. fluid intake; Keep this leaflet. You may need to read it again. if you have ever been diagnosed with high potassium levels in If you have any further questions, please ask your doctor or the blood; pharmacist. Tell your doctor if you think any of these apply to you. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are Warning the same as yours. Medicines such as these Meloxicam tablets may be If any of the side effects become serious, or if you notice associated with a small increased risk of heart attack or any side effects not listed in this leaflet, please tell your doctor or stroke. Any risk is more likely with high doses and prolonged pharmacist. treatment. Do not exceed the recommended dose or duration of treatment. IN THIS LEAFLET: Discuss your treatment with your doctor or pharmacist if you have heart problems, have previously had a stroke or you think you 1. What Meloxicam orodispersible tablets are and what might be at risk of conditions such as high blood pressure, they are used for diabetes or high cholesterol, or if you are a smoker. 2 . Before you take Meloxicam tablets 3. How to take Meloxicam tablets Taking other medicines When you are taking Meloxicam tablets, do not take any other 4.
    [Show full text]
  • (Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
    TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
    [Show full text]
  • Post Marketing Safety Data Analysis Reveals Increased Propensity For
    Post Marketing Safety Data Analysis Reveals Increased Propensity for Severe Cardiovascular and Cerebrovascular Side Effects in Patients Taking Celecoxib Compared to Other NSAIDs Aarti Patel, PharmD Candidate, Tigran Makunts, PharmD, Ruben Abagyan, Ph.D. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA ABSTRACT RESULTS Non-steroidal anti-inflammatory medications, NSAIDS, are commonly used Cardiovascular ADR Report Frequencies Cardiovascular ADR Report Frequencies Odds ratios of cardiovascular ADR worldwide for their analgesic and anti-inflammatory properties, and are deemed out of 100,202 NSAID Reports Among Male and Female Celecoxib Users among Celecoxib male users when safe for over the counter access. NSAIDS as a class have been associated with Myocardial Infarction 4.79 compared to female users cardiovascular, CV, cerebrovascular, CVA, and hypertension, side effects, with Cerebrovascular Accident 3.66 Cerebrovascular 9.69 Accident 11.23 rofecoxib being removed from the market due to these toxicities. However, the Chest Pain 0.85 Cerebrovascular Accident 1.18 risks of heart attack and stroke were deemed similar in all currently marketed Hypertension 0.73 Palpitations 0.49 1.77 NSAIDs. The growing concern over the potentially fatal CV and CVA warranted ADR Hypertension Hypertension 1.16 Hypotension 0.46 ADR 2.05 FEMALES further studies to quantify the associations these side effects. Here, we ADR Atrial Fibrillation MALES analyzed over twelve million reports in the FDA Adverse Event Reporting 0.29 Congestive Heart Failure 0.28 12.16 System, FAERS, to evaluate the reporting odds ratios of hypertension, Myocardial Infarction Myocardial Infarction 2.42 Tachycardia 0.25 myocardial infarction, and stroke in patients taking individual NSAIDs and 25.11 0 1 2 3 4 5 acetaminophen as monotherapy.
    [Show full text]
  • 2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report Date: September 2003 Update 2 Report Date: May 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Mark Helfand, MD, MPH Kim Peterson, MS Tracy Dana, MLS Carol Roberts, BS Produced by Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically(see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 3 Drug Effectiveness Review Project TABLE OF CONTENTS Evidence Table 1. Systematic reviews…………………………………………………………………3 Evidence Table 2. Randomized-controlled trials………………………………………………………9 Evidence Table 3.
    [Show full text]
  • Mobic Tablets Meloxicam Consumer Medicine Information
    Mobic Tablets meloxicam Consumer Medicine Information What is in this leaflet Although Mobic can relieve the bypass graft or major vascular symptoms of pain and inflammation, surgery This leaflet answers some common it will not cure your condition. Mobic • have a disease of the heart with questions about Mobic. belongs to a family of medicines shortness of breath, and swelling called Non-Steroidal Anti- of the feet or lips due to fluid It does not contain all the available Inflammatory Drugs (NSAIDs). information. build-up These medicines work by relieving • experience bleeding from the It does not take the place of talking to pain and inflammation. your doctor or pharmacist. stomach, gut or any other Ask your doctor if you have any bleeding All medicines have risks and questions about why this medicine • benefits. Your doctor has weighed has been prescribed for you. had a stroke resulting from a the risks of you taking Mobic against bleed in the brain or have a Your doctor may have prescribed it bleeding disorder the benefits they expect it will have for another reason. for you. • had a heart attack This medicine is available only with • If you have any concerns about a doctor's prescription. have galactose intolerance taking this medicine, ask your • are pregnant or intend to become doctor or pharmacist. pregnant This leaflet was last updated on the • have a peptic (stomach) ulcer date at the end of this leaflet. More Before you take Mobic • have or have had inflammation of recent information may be available. the lining of the stomach or The latest Consumer Medicine When you must not take it Information is available from your bowel (e.g.
    [Show full text]
  • Motrin® Ibuprofen Tablets, USP
    Effective Date: 01/20/2007 Motrin® Ibuprofen Tablets, USP Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS). • MOTRIN tablets are contraindicated for treatment of peri- operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). DESCRIPTION MOTRIN tablets contain the active ingredient ibuprofen, which is (±) - 2 - (p - isobutylphenyl) propionic acid. Ibuprofen is a white powder with a melting point of 74-77° C and is very slightly soluble in water (<1 mg/mL) and readily soluble in organic solvents such as ethanol and acetone. The structural formula is represented below: MOTRIN tablets, a nonsteroidal anti-inflammatory drug (NSAID), is available in 400 mg, 600 mg, and 800 mg tablets for oral administration. Inactive ingredients: carnauba wax, colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, propylene glycol, titanium
    [Show full text]
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug
    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Non-Selective Oral Nonsteroidal Anti-Inflammatory Drugs AHFS Classification: 28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents Diclofenac Etodolac Fenoprofen Flurbiprofen Ibuprofen Indomethacin Ketoprofen Ketorolac Mefenamic Acid Meloxicam Nabumetone Naproxen Oxaprozin Piroxicam Sulindac Tolmetin Final Report April 2018 Review prepared by: Elena Martinez Alonso, B.Pharm., Medical Writer Vicki Frydrych, B.Pharm., Pharm.D., Clinical Pharmacist Valerie Gonzales, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor, Clinical Pharmacist Michelle Fiander, MA, MLIS, Research Assistant Professor, Evidence Synthesis Librarian Joanne LaFleur, PharmD, MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved 1 Contents Executive Summary ...................................................................................................................................... 3 Introduction ................................................................................................................................................... 6 Table 1. FDA-Approved Oral Non-selective NSAIDs......................................................................... 7 Table 2. FDA-Approved Indication for Oral Non-selective NSAIDs ...............................................
    [Show full text]
  • Single Dose of Diclofenac Or Meloxicam for Control of Pain, Facial Swelling, and Trismus in Oral Surgery
    Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 (1):e127-34. Diclofenac versus meloxicam in oral surgery Journal section: Oral Surgery doi:10.4317/medoral.20925 Publication Types: Research http://dx.doi.org/doi:10.4317/medoral.20925 Single dose of diclofenac or meloxicam for control of pain, facial swelling, and trismus in oral surgery Mariana Orozco-Solís 1, Yazmín García-Ávalos 2, Celeste Pichardo-Ramírez 2, Francisco Tobías-Azúa 2, Juan-Ramón Zapata-Morales 3, Othoniel-Hugo Aragon-Martínez 4, Mario-Alberto Isiordia-Espinoza 5 1 DDS, Departamento de Estomatología, Unidad Médica Familiar No. 02, Instituto Mexicano del Seguro Social, Delegación San Luis Potosí, S.L.P., México 2 DDS, Departamento de Investigación y Postgrado, Escuela de Odontología, Universidad Cuauhtémoc, plantel San Luis Poto- sí, S.L.P., México 3 MSc, PhD, Departamento de Farmacia, División de Ciencias Naturales y Exactas, Universidad de Guanajuato, Guanajuato, México 4 MSc, PhD, Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, S.L.P., México 5 DDS, MSc, PhD, Departamento de Farmacología, Facultad de Odontología, Universidad Autónoma de Baja California, Mexi- cali, México Orozco-Solís M, García-Ávalos Y, Pichardo-Ramírez C, Tobías-Azúa F, Zapata-Morales JR, Aragon-Martínez OH, Isiordia-Espinoza MA. Single Correspondence: dose of diclofenac or meloxicam for control of pain, facial swelling, and Facultad de Odontología trismus in oral surgery. Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 Universidad Autónoma de Baja California (1):e127-34. Calle Zotoluca y Chinampas s/n http://www.medicinaoral.com/medoralfree01/v21i1/medoralv21i1p127.pdf Fraccionamiento Calafia C.P.
    [Show full text]
  • How Does Meloxicam (Mobicox?) Compare to Other Nsaids and Csis
    The Rx Files: Q&A Summary February 2001 â Update on Meloxicam (Mobicoxâ) & COX-2 Selectivity COX-2 Selectivity/Specificity adverse GI events.10 This data must be cautiously interpreted wThere is a lot of discussion regarding the relative COX-2 due to the inherent limitations of the meta-analysis, such as selectivity of meloxicam compared to celecoxib (Celebrexâ) variability of trial outcomes, and the low dosage of meloxicam and rofecoxib (Vioxxâ). A December 2000 RxFiles Q&A used in most trials. Summary regarding meloxicam stated that it had “relatively wMeloxicam appears to have better GI tolerance than non- selective but not specific COX-2 inhibition” as discussed in selective NSAIDs. To what extent ulcers and complicated a variety of literature.1,2,3,4,5 Boehringer Ingelheim (Canada) ulcers are also reduced remains to be established. Ltd. (BICL) has been detailing meloxicam as an agent with wMajor trials evaluating the safety of the other COX-2 selective COX-2 selectivity comparable to celecoxib based on data drugs, celecoxib (Celebrexâ) and rofecoxib (Vioxxâ) have been from BICL sponsored work of Warner et al.6 This research published. These trials differ from the large-scale meloxicam measured NSAID inhibition of COX-1 when COX-2 trials as dosages were 2-4X higher than usually enzyme activity is inhibited by 80%. It found that both recommended and trial length was longer (see Table). meloxicam and celecoxib were 5-50 fold selective for COX- §The CLASS11 study compared celecoxib to non-selective 2, with rofecoxib being >50 fold COX-2 selective. The NSAIDs (ibuprofen and diclofenac).
    [Show full text]
  • Tolfenamic Acid and Meloxicam Both Provide an Adequate Degree of Postoperative Analgesia in Dogs Undergoing Ovariohysterectomy
    Veterinarni Medicina, 62, 2017 (06): 333–341 Original Paper doi: 10.17221/143/2016-VETMED Tolfenamic acid and meloxicam both provide an adequate degree of postoperative analgesia in dogs undergoing ovariohysterectomy X.Y. Hu, L. Luan, W. Guan, J. Shi, Y.B. Zhao, H.G. Fan* Department of Veterinary Surgery, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China *Corresponding author: [email protected] ABSTRACT: This study was aimed at comparing the postoperative analgesic effects of tolfenamic acid and meloxi- cam in dogs undergoing ovariohysterectomy. Ovariohysterectomy was performed in 24 female dogs. All dogs were administered pre-anaesthetic medication comprised of 0.02 mg/kg i.m. acepromazine, and general anaesthesia was induced with i.v. propofol (4–6 mg/kg) and maintained with 1.5–2.0% isoflurane. Dogs were divided into three groups (n = 8). Following induction of anaesthesia, group C received 0.05 ml/kg sterile saline i.m.; group T received 4 mg/kg tolfenamic acid i.m.; group M received 0.2 mg/kg meloxicam s.c. Heart rate, respiratory rate, rectal tem- perature, mean arterial pressure and arterial oxygen saturation of haemoglobin were monitored intraoperatively. Pain was assessed using the short form of the Glasgow composite pain scale (SF-GCPS) by two observers who were blinded to the treatment groups; pain was assessed at the time of pre-medication (baseline), and at 2, 4, 6, 8, 12 and 24 h after extubation. Rescue analgesia (0.2 mg/kg i.m. methadone) was administered to any dog with an SF-GCPS score of greater than or equal to six during postoperative monitoring.
    [Show full text]
  • Nsaids in Cats
    ISFM and AAFP Consensus Guidelines Long-term use of NSAIDs in cats Clinical Practice A preprint from the Journal of Feline Medicine and Surgery Volume 12, July 2010 Journal of Feline Medicine and Surgery (2010) 12, 519 doi:10.1016/j.jfms.2010.05.003 EDITORIAL NSAIDs and cats – it’s been a long journey Although the first This issue of JFMS contains the first ever panel have covered much valuable ground: international consensus guidelines ✜ To set the scene they consider how use of NSAIDs on the long-term use of non-steroidal common chronic pain can be in cats, typically was probably anti-inflammatory drugs (NSAIDs) in cats. related to degenerative joint disease, This timely publication, which appears on idiopathic cystitis, trauma and cancer. by Hippocrates, pages 521–538 (doi:10.1016/j.jfms.2010.05.004), ✜ They then explain how and why NSAIDs is a collaborative enterprise by the International can have such positive and, potentially, it has taken until Society of Feline Medicine (ISFM) and negative actions. now for cats to American Association of Feline Practitioners ✜ They consider the best ways of enhancing (AAFP). It has been compiled by a panel of owner and cat compliance, make suggestions gain the benefit of world leaders in the understanding of pain about sensible dosing frequencies, timing of in cats and, without doubt, is essential reading medication and accuracy of dosing, and the long-term use for all small animal veterinary surgeons. emphasize the importance of always using of these drugs. It is interesting to reflect that although the ‘lowest effective dose’.
    [Show full text]
  • Indocin® (Indomethacin) Oral Suspension
    INDOCIN® (INDOMETHACIN) ORAL SUSPENSION Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at a greater risk. (See WARNINGS.) • INDOCIN is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS.) DESCRIPTION Suspension INDOCIN1 for oral use contains 25 mg of indomethacin per 5 mL, alcohol 1%, and sorbic acid 0.1% added as a preservative and the following inactive ingredients: antifoam AF emulsion, flavors, purified water, sodium hydroxide or hydrochloric acid to adjust pH, sorbitol solution, and tragacanth. Indomethacin is a non-steroidal anti-inflammatory indole derivative designated chemically as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. 1 Indomethacin is practically insoluble in water and sparingly soluble in alcohol. It has a pKa of 4.5 and is stable in neutral or slightly acidic media and decomposes in strong alkali. The suspension has a pH of 4.0-5.0. The structural formula is: 1 Registered trademark of MERCK & CO., Inc., Whitehouse Station, NJ U.S.A. and licensed to Iroko Pharmaceuticals, LLC, Philadelphia, PA, U.S.A.
    [Show full text]